CN1040534C - 制备纤维蛋白原受体拮抗剂的方法 - Google Patents

制备纤维蛋白原受体拮抗剂的方法 Download PDF

Info

Publication number
CN1040534C
CN1040534C CN93102134A CN93102134A CN1040534C CN 1040534 C CN1040534 C CN 1040534C CN 93102134 A CN93102134 A CN 93102134A CN 93102134 A CN93102134 A CN 93102134A CN 1040534 C CN1040534 C CN 1040534C
Authority
CN
China
Prior art keywords
ambient temperature
liters
alkyl
compound
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN93102134A
Other languages
English (en)
Chinese (zh)
Other versions
CN1076442A (zh
Inventor
钟尧亮
赵大连
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN1076442A publication Critical patent/CN1076442A/zh
Application granted granted Critical
Publication of CN1040534C publication Critical patent/CN1040534C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
CN93102134A 1992-02-28 1993-02-27 制备纤维蛋白原受体拮抗剂的方法 Expired - Fee Related CN1040534C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84369092A 1992-02-28 1992-02-28
US843,690 1992-02-28

Publications (2)

Publication Number Publication Date
CN1076442A CN1076442A (zh) 1993-09-22
CN1040534C true CN1040534C (zh) 1998-11-04

Family

ID=25290743

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93102134A Expired - Fee Related CN1040534C (zh) 1992-02-28 1993-02-27 制备纤维蛋白原受体拮抗剂的方法

Country Status (12)

Country Link
US (1) US5312923A (enExample)
CN (1) CN1040534C (enExample)
AU (1) AU3731393A (enExample)
CZ (1) CZ282770B6 (enExample)
FI (1) FI106024B (enExample)
HU (1) HU223578B1 (enExample)
RO (1) RO115724B1 (enExample)
RU (1) RU2113432C1 (enExample)
SK (1) SK280164B6 (enExample)
TW (1) TW232008B (enExample)
WO (1) WO1993016994A1 (enExample)
YU (1) YU13293A (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102241622A (zh) * 2010-05-13 2011-11-16 上海医药工业研究院 一种制备盐酸替罗非班的方法
CN115181058A (zh) * 2021-04-01 2022-10-14 武汉武药科技有限公司 组合物及其质量控制方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0925063A4 (en) * 1996-07-01 2000-12-27 Lilly Co Eli Blood-glucose-lowering and lipid-lowering compounds
US6623981B2 (en) * 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
GB9812088D0 (en) * 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
DE69917278T2 (de) * 1998-07-31 2005-05-19 Eli Lilly And Co., Indianapolis Heterocyclyl sulphonamid derivate
US6518244B2 (en) 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
CN101870672B (zh) * 2010-07-05 2011-08-24 武汉同源药业有限公司 一种化合物盐酸替罗非班的制备方法
CN101898998B (zh) * 2010-08-25 2012-09-19 武汉武药科技有限公司 一种盐酸替罗非班中间体的制备方法
CN102875449B (zh) * 2012-10-15 2014-08-06 天津南开允公医药科技有限公司 盐酸替罗非班异构体分离方法及d构型盐酸替罗非班定量方法
CN103848775A (zh) * 2012-11-29 2014-06-11 上海信谊药厂有限公司 制备盐酸替罗非班的方法
CN109608387A (zh) * 2019-01-02 2019-04-12 海门慧聚药业有限公司 盐酸替罗非班的制备
CN111100066B (zh) * 2019-11-29 2021-07-30 石药集团恩必普药业有限公司 一种盐酸替罗非班中间体及盐酸替罗非班的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3412138A (en) * 1965-12-17 1968-11-19 Ibm Alkylation of tyrosine
EP0478363A2 (en) * 1990-09-27 1992-04-01 Merck & Co. Inc. Novel sulfonamide fibrinogen receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3412138A (en) * 1965-12-17 1968-11-19 Ibm Alkylation of tyrosine
EP0478363A2 (en) * 1990-09-27 1992-04-01 Merck & Co. Inc. Novel sulfonamide fibrinogen receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.HET CHEM VOL3 1966.1.1 G.M.Sigerman et al Synthesis of Alkyraninoethane-thioesulfuric Acids subst *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102241622A (zh) * 2010-05-13 2011-11-16 上海医药工业研究院 一种制备盐酸替罗非班的方法
CN115181058A (zh) * 2021-04-01 2022-10-14 武汉武药科技有限公司 组合物及其质量控制方法
CN115181058B (zh) * 2021-04-01 2024-06-11 武汉武药科技有限公司 组合物及其质量控制方法

Also Published As

Publication number Publication date
RU94041212A (ru) 1996-06-20
HUT70545A (en) 1995-10-30
WO1993016994A1 (en) 1993-09-02
SK280164B6 (sk) 1999-09-10
HU223578B1 (hu) 2004-09-28
FI106024B (fi) 2000-11-15
RO115724B1 (ro) 2000-05-30
US5312923A (en) 1994-05-17
AU3731393A (en) 1993-09-13
CZ205694A3 (en) 1995-10-18
RU2113432C1 (ru) 1998-06-20
FI943934L (fi) 1994-10-05
TW232008B (enExample) 1994-10-11
YU13293A (sh) 1997-07-31
CN1076442A (zh) 1993-09-22
SK102494A3 (en) 1995-04-12
FI943934A0 (fi) 1994-08-26
CZ282770B6 (cs) 1997-10-15
HU9402462D0 (en) 1994-10-28

Similar Documents

Publication Publication Date Title
CN1040534C (zh) 制备纤维蛋白原受体拮抗剂的方法
JP2001525396A (ja) マトリックスメタロプロテアーゼ（ｍｍｐ）阻害剤としてのヒドロキサム酸誘導体
CN88101234A (zh) 由杂芳基和四氢化萘基双取代的具有类似类视色素活性的乙炔
JP2012505224A (ja) ベンダムスチンの調製方法
CN1870998A (zh) Ccr－2拮抗剂盐
CN1040440C (zh) 去氢环黄皮酰胺衍生物的制备方法
CN1050832C (zh) 制备纤维蛋白原受体拮抗剂的方法
CN101160286B (zh) 制备ccr-2拮抗剂的方法
CN1131864C (zh) 吗啉衍生物的化学合成方法
CN105646285B (zh) 一种维兰特罗中间体及其制备方法和应用
WO2014206257A1 (zh) 一种2-羧酸吡咯烷衍生物的制备方法
US7728135B2 (en) Synthesis of CCR5 receptor antagonists
CN1487916A (zh) 方法
US6486320B2 (en) Preparation of camptothecin and of its derivatives
KR100886002B1 (ko) 4-테트라졸릴-4-페닐피페리딘 화합물의 제조방법
JP4829418B2 (ja) 光学活性なハロヒドリン誘導体およびその使用方法
CN115925615A (zh) 一种光学纯2-甲基哌啶-5-胺的制备方法
KR100758522B1 (ko) 신규 벤즈아미드 유도체 및 이의 제조법
CN1934110A (zh) 地舍平的半合成方法
US10479769B2 (en) Processes for the preparation of eluxadoline
JPH05221947A (ja) シクロプロパン誘導体の製法
JP2542274B2 (ja) ３―［４―（１―イミダゾリルメチル）フェニル］―２―プロペン―１―アル及びその製造方法
CN1290247A (zh) 制备抗叶酸剂的方法和中间体
RU2566818C2 (ru) Способ получения (±)n-[1-(4-фторфенил)-2-(1-этилпиперидин-4-ил)этил]-4-нитробензамида или его фармацевтически приемлемых солей и промежуточное соединение для его получения
CN1709873A (zh) 一类哌啶化合物及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee